Antiepileptic drug utilization in pediatric patients
Related Experiment Videos
Insights
Children need higher doses of antiepileptic drugs due to significant variability. Monitoring drug levels is crucial for safe and effective epilepsy treatment in pediatric patients.
Area of Science:
- Pediatric Pharmacology
- Neuroscience
- Clinical Pharmacy
Background:
- Pediatric patients often require higher relative doses of antiepileptic drugs (AEDs) compared to adults.
- Significant inter-individual pharmacokinetic variability exists in children, making average dosing inaccurate.
- Drug elimination and dosage requirements change rapidly during early life, necessitating frequent adjustments.
Purpose of the Study:
- To highlight the pharmacokinetic variability of AEDs in pediatric populations.
- To emphasize the importance of therapeutic drug monitoring in children with epilepsy.
- To discuss age-related differences in AED dosing and metabolism.
Main Methods:
- Review of pharmacokinetic principles in neonates, infants, and children.
- Analysis of age-dependent drug clearance and elimination rates.
- Discussion of nonlinear kinetics observed with specific AEDs like phenytoin.
Main Results:
- Newborns exhibit slow drug elimination and wide pharmacokinetic ranges.
- Infants (2-12 months) show the highest drug clearance, requiring significantly larger relative doses.
- Dosage requirements decrease with age, reaching adult levels by 10-15 years.
- Phenytoin demonstrates nonlinear kinetics across all age groups, including children.
Conclusions:
- AED pharmacokinetics are highly variable in children, presenting significant treatment challenges.
- Frequent dosage adjustments are critical in the first 6 weeks of life due to intrapatient variability.
- Therapeutic drug concentration monitoring is essential for optimizing epilepsy management in pediatric patients.
Abstract:
Children require larger relative doses of antiepileptic drugs than adults, and because of the greater patient-to-patient variability among children, an "average" dose is less likely to be correct for a given child. Newborns with convulsions initially have very slow drug elimination; as a group, they also have the widest range of pharmacokinetic values. After the first week of life, drug eliminating mechanisms mature and drug dosage requirements often increase dramatically. Thus in the first 6 weeks of life, intrapatient variation is a significant problem and frequent dosage changes are usually required. Thereafter a given child's kinetics are fairly stable. Infants 2 to 12 months old have the highest rates of drug clearance and often require relative doses that are 3 to 5 times larger than doses for adults. After infancy, relative dosage requirements progressively decline until adult values are reached by 10 to 15 years of age. Newborns, infants, and children, as well as adults, have nonlinear kinetics for phenytoin. Thus a wide range of apparent half-lives occur in children, depending on the phenytoin concentration and other factors. Because the kinetics of antiepileptic drugs are so highly variable in children, antiepileptic drug concentration measurements are an essential aspect of the contemporary treatment of children with epilepsy.